New Brightline Transformation Compass Guides Organizations to Successfully Navigate Transformation Initiatives
The need for global organizations to be agile and responsive in a digital age is widely recognized, yet leaders of large global organizations still struggle with executing on transformation initiatives. The Wall Street Journal recently reported on a survey of directors, CEOs, and senior executives that found that transformation was their No. 1 risk in 2019. The research, conducted by the NC State Enterprise Risk Management Initiative, predicted that the top risks for organizations in 2019 would be “existing operations meeting performance expectations,” and “competing against ‘born digital’ firms.” For organizations to compete with their new digital competitors, they must rapidly transform.
To help organizations overcome obstacles to transformation, Brightline™, a Project Management Institute (PMI) initiative, has released its new transformation framework at the Strategy@Work conference in New York City. The Brightline Transformation Compass is an invaluable playbook for executives who are on the front line facing the challenge of transformation organizations.
"Transformation efforts today are more likely to fail than succeed,” said Sunil Prashara, President and CEO of Project Management Institute. “And when transformations fail, it costs organizations time, money, and effort. To help improve these results and avoid waste, PMI started Brightline as a strategic initiative to bridge the gap between strategy design and delivery. Brightline creates much-needed tools, including the new Brightline Transformation Compass, to help senior executives accomplish this vision.”
"The key to a successful transformation is building a movement that aligns inside-out and outside-in approaches,” noted Dr. Behnam Tabrizi, the co-author of the framework’s Compass Methodology. Dr. Tabrizi is a renowned expert in transformation and has served on the teaching faculty at Stanford University and its executive programs for the past 25 years. He has studied over one thousand transformations and advised more than 100 global organizations in their transformation. A transformation guided by the Brightline Transformation Compass is led by committed senior leaders inside the organization and authored and driven by large numbers of their own employees – the management and front-line team members who have a stake in the organization’s success.
The Brightline Transformation Compass is built on five critical and mutually reinforcing building blocks for successful transformation. The Compass Methodology, a three-step process that helps leaders drive transformation efforts and start seeing tangible results in the most rapid way, supports these building blocks. The methodology guides leaders in inspiring their organization for change by mobilizing key elements to drive the change, and in shifting the organization to effect transformation.
By making the step-by-step transformation framework playbook available for free, the Brightline Transformation Compass empowers leaders and employees to successfully lead and implement transformation across entire organizations.
Visit compass.brightline.org to download and apply the framework to your change initiatives.
About Brightline Initiative
Brightline™ is a Project Management Institute (PMI) initiative, together with leading global organizations, dedicated to helping executives’ bridge the expensive and unproductive gap between strategy design and delivery. Learn more at www.brightline.org.
Brightline Coalition
Project Management Institute (PMI) – Boston Consulting Group – Bristol-Myers Squibb – Saudi Telecom Company – Lee Hecht Harrison – Agile Alliance – NetEase
Academic and Research Collaboration
Technical University of Denmark – MIT Consortium for Engineering Program Excellence – Duke Corporate Education – Insper – IESE – University of Tokyo Global Teamwork Lab – Blockchain Research Institute
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005265/en/
Contact information
Tahirou Assane
Director of Operations, Brightline Initiative
Tahirou.Assane@Brightline.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom